ScreenPoint Medical’s new Transpara powered by Fusion AI cleared for 2D and 3D mammography in the USA.

The latest version of Transpara, the leading AI system that identifies potential breast cancers faster and earlier than before, has been cleared after rigorous investigation by the FDA. Transpara is already CE marked.  Transpara, developed by ScreenPoint Medical, is in daily use in over 200 healthcare facilities in more than 25 countries around the world.  Read the full release here